Skip to main content

The independent medical news service

21-09-2020 | Oncology | News | Article

Nivolumab–cabozantinib ‘a potential first-line option’ for advanced RCC

The phase 3 CheckMate 9ER trial has demonstrated significantly improved outcomes with the combination of nivolumab and cabozantinib versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma.

26-08-2020 | Oncology | News | Article

Gut microbiome linked to RCC immunotherapy efficacy

Research has demonstrated an association between the gut microbiome composition and response to treatment with immune checkpoint inhibitors in patients with metastatic renal cell carcinoma.

14-08-2020 | Oncology | News | Article

Meta-analysis confirms ICI benefit for sarcomatoid RCC

Results from a meta-analysis support use of immune checkpoint inhibitors for the treatment of sarcomatoid renal cell carcinoma.

14-07-2020 | Oncology | News | Article

Data support post-ICI cabozantinib use in metastatic clear cell RCC

Real-world study data show that a high proportion of patients with metastatic clear cell renal cell carcinoma gain clinical benefit from treatment with cabozantinib following progression with immune checkpoint inhibitors.

03-07-2020 | Oncology | News | Article

Potential for anticancer, COVID-19 drug interactions highlighted

A French team has drawn attention to the potential for drug–drug interactions between anticancer medications and agents being used or tested for the treatment of COVID-19.

30-06-2020 | Oncology | News | Article

Salvage nivolumab–ipilimumab shows potential for some metastatic RCC patients

The combination of nivolumab and ipilimumab demonstrates antitumor activity and acceptable toxicity in patients with metastatic renal cell carcinoma previously exposed to PD-1 or PD-L1 inhibitors, say the authors of a chart review.

Image Credits